Efficacy of Ivermectin in COVID-19

• Status: Recruiting
• Trial end date: 2020-07-01
• Target enrollment: 0
• Participant gender: All

Summary

It is a randomized controlled trial to assess the efficacy of Ivermectin in COVID-19. Patient recruited will be assigned to two groups one group will be given ivermectin with standard chloroquine regimen and the other group will be receiving chloroquine only. Out come will be recorded by documenting PCR reports at 48, 96 and 144 hours.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Combined Military Hospital, Pakistan
• Treatments: Ivermectin

Criteria

Inclusion Criteria:

• Provision of signed and dated informed consent form

• Stated willingness to comply with all study procedures and availability for the duration of the study

• Male or female, aged 15 to 65 years

• In good general health with no or mild to moderate symptoms of Corona virus disease

• PCR positive for SARS-Cov-2.

• Ability to take oral medication and be willing to adhere to the drug intake regimen

Exclusion Criteria:

• Severe symptoms likely attributed to Cytokine Release Storm.

• Malignant diseases, diabetes mellitus, chronic kidney disease and cirrhosis liver with CPT class B or C.